Skip to main content
Log in

Limitationen der Lipid-Therapie

Progress trotz Lipoproteinapherese

  • Fortbildung
  • Lipidsprechstunde
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Tselmin S et al. An elevated lipoprotein(a) plasma level as a cardiovascular risk factor. Atheroscler Suppl. 2015;18:257–62

    Article  CAS  Google Scholar 

  2. Schatz U et al. Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic. Atheroscler Suppl. 2019; in press

  3. Leebmann J, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128(24):2567–76

    Article  CAS  Google Scholar 

  4. Roeseler E et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol. 2016;36(9):2019–27

    Article  CAS  Google Scholar 

  5. Emmrich U, Hohenstein B, Julius U. Actual situation of lipoprotein apheresis in Saxony in 2013. Atheroscler Suppl. 2015;18:215–25

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ulrike Schatz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schatz, U., Fischer, S., Tselmin, S. et al. Progress trotz Lipoproteinapherese. CV 19, 27–28 (2019). https://doi.org/10.1007/s15027-019-1635-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-019-1635-9

Navigation